114 related articles for article (PubMed ID: 15640527)
1. Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients.
Würtz SØ; Christensen IJ; Schrohl AS; Mouridsen H; Lademann U; Jensen V; Brünner N
Mol Cell Proteomics; 2005 Apr; 4(4):483-91. PubMed ID: 15640527
[TBL] [Abstract][Full Text] [Related]
2. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.
Schrohl AS; Christensen IJ; Pedersen AN; Jensen V; Mouridsen H; Murphy G; Foekens JA; Brunner N; Holten-Andersen MN
Mol Cell Proteomics; 2003 Mar; 2(3):164-72. PubMed ID: 12672830
[TBL] [Abstract][Full Text] [Related]
3. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Schrohl AS; Holten-Andersen MN; Peters HA; Look MP; Meijer-van Gelder ME; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 2004 Apr; 10(7):2289-98. PubMed ID: 15073104
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study.
Thorsen SB; Christensen SL; Würtz SO; Lundberg M; Nielsen BS; Vinther L; Knowles M; Gee N; Fredriksson S; Møller S; Brünner N; Schrohl AS; Stenvang J
BMC Cancer; 2013 Dec; 13():598. PubMed ID: 24330623
[TBL] [Abstract][Full Text] [Related]
5. High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study.
Kuvaja P; Würtz SØ; Talvensaari-Mattila A; Brünner N; Pääkkö P; Turpeenniemi-Hujanen T
Cancer Biomark; 2007; 3(6):293-300. PubMed ID: 18048967
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
7. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study.
Würtz SØ; Møller S; Mouridsen H; Hertel PB; Friis E; Brünner N
Mol Cell Proteomics; 2008 Feb; 7(2):424-30. PubMed ID: 17998244
[TBL] [Abstract][Full Text] [Related]
8. Tissue inhibitor of metalloproteinases-1 in breast cancer.
Würtz SØ; Schrohl AS; Sørensen NM; Lademann U; Christensen IJ; Mouridsen H; Brünner N
Endocr Relat Cancer; 2005 Jun; 12(2):215-27. PubMed ID: 15947098
[TBL] [Abstract][Full Text] [Related]
9. Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.
Klintman M; Ørnbjerg Würtz S; Christensen IJ; Braemer Hertel P; Fernö M; Malmberg M; Mouridsen H; Cold F; Schrohl AS; Foekens JA; Malmström P; Brünner N
Breast Cancer Res Treat; 2010 Jun; 121(2):365-71. PubMed ID: 19653096
[TBL] [Abstract][Full Text] [Related]
10. High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma.
Kuvaja P; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Int J Cancer; 2008 Aug; 123(4):846-51. PubMed ID: 18506691
[TBL] [Abstract][Full Text] [Related]
11. Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Miyagi Y
Gastric Cancer; 2006; 9(2):106-13. PubMed ID: 16767366
[TBL] [Abstract][Full Text] [Related]
12. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
13. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
14. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
15. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma.
Kuvaja P; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
Oncology; 2005; 68(2-3):196-203. PubMed ID: 16006757
[TBL] [Abstract][Full Text] [Related]
16. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma.
Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Breast Cancer Res Treat; 2005 Jan; 89(1):29-34. PubMed ID: 15666194
[TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis.
Fernandez-Garcia B; Eiró N; Marín L; González-Reyes S; González LO; Lamelas ML; Vizoso FJ
Histopathology; 2014 Mar; 64(4):512-22. PubMed ID: 24117661
[TBL] [Abstract][Full Text] [Related]
18. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
19. Expression and Clinical Significance of Metalloproteases and Their Inhibitors by Endothelial Cells From Invasive Breast Carcinomas.
Cid S; Eiro N; González LO; Beridze N; Vazquez J; Vizoso FJ
Clin Breast Cancer; 2016 Aug; 16(4):e83-91. PubMed ID: 27266802
[TBL] [Abstract][Full Text] [Related]
20. Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.
Kuvaja P; Hulkkonen S; Pasanen I; Soini Y; Lehtonen S; Talvensaari-Mattila A; Pääkkö P; Kaakinen M; Autio-Harmainen H; Hurskainen T; Lehenkari P; Turpeenniemi-Hujanen T
Exp Cell Res; 2012 Jun; 318(10):1094-103. PubMed ID: 22465225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]